Company / Cash per Share
Janux Therapeutics, Inc. Cash per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$0.84
FY2025
5-year range
$0.44 / $8.01
FY2021-FY2025
Trend
-89.5%
vs FY2024
Sector context
#158 of 207
Health Care
What the data says
Janux Therapeutics, Inc.'s cash per share of $0.84 is lower than 76% of companies in the Health Care sector (FY2025). Improved from $0.44 to $0.84 over the past 2 years.
Based on SEC 10-K filings.
0.84 in FY2025 with a 5-year CAGR of -37.0%.
Improved from $0.44 to $0.84 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -12.0%
- 5-Year CAGR
- -37.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 207This company $0.84 Sector average $67.39
▼
-98.7% below sector average
Key checks
Key Insights
- In FY2025, cash per share decreased 89.5% year-over-year.
- Ranks #158 out of 207 companies in the Health Care sector.
- Peak cash per share was recorded in FY2020.
- Lowest cash per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.84 | -89.5% |
| FY2024 | $8.01 | +1736.1% |
| FY2023 | $0.44 | -64.8% |
| FY2022 | $1.24 | -18.0% |
| FY2021 | $1.51 | -82.3% |
| FY2020 | $8.54 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026